Join the High Cholesterol - Familial Heterozygous group to help and get support from people like you.
High Cholesterol - Familial Heterozygous News
Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous
U.S. FDA Approves Broad New Labels for Nexletol and Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for...
Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® ...
Statin Meds & Cholesterol: What You Need to Know
TUESDAY, March 5, 2024 – Statins have become the miracle medicine of modern heart care, lowering cholesterol levels and and guarding against heart attacks in millions of Americans. In fact, a...
Statin Meds & Cholesterol: What You Need to Know
TUESDAY, March 5, 2024 – Statins have become the miracle medicine of modern heart care, lowering cholesterol levels and and guarding against heart attacks in millions of Americans. In fact, a...
2015 to 2021 Saw Marked Rise in PCSK9 Inhibitor Utilization
TUESDAY, March 5, 2024 – Barriers for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use persist for cholesterol management, according to a research letter published online Feb. 16...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s Nexletol (bempedoic acid) Tablet and Nexlizet (bempedoic acid and ezetimibe) Tablet
Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA...
Watching Your Cholesterol? Virtual Doctor Visits Work Just as Well
THURSDAY, Dec. 7, 2023 – In a win for telemedicine, new research shows that folks fighting high cholesterol benefit just as much from online coaching as they do from in-person visits with a...
Statin Use Increased From 1999-2000 to 2013-2014, Then Plateaued
MONDAY, Dec. 4, 2023 – Overall statin use for primary prevention increased since 1999 to 2000 but has plateaued since 2013 to 2014, according to a research letter published online Dec. 5 in the...
Lipid-Lowering Drugs Save Lives, but Use Decreasing
FRIDAY, Dec. 1, 2023 – Lipid-lowering drugs for primary prevention are associated with a significant survival benefit, but use has decreased over time, according to a study published online Nov. 16...
AHA News: Here's the Latest on Dietary Cholesterol and How It Fits In With a Healthy Diet
FRIDAY, Aug. 25, 2023 (American Heart Association News) – For more than half a century, scientists have debated the role of dietary cholesterol in a healthy diet. Because it was often associated...
Whether or Not You Get Heart-Healthy Statins May Depend on Race
FRIDAY, May 12, 2023 – Millions of Americans take cholesterol-lowering drugs called statins, but a new study finds Black and Hispanic adults get the drugs less often than white people do. “This adds t...
FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C)
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and...
FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
THOUSAND OAKS, Calif., Sept. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and ...
FDA Medwatch Alert: FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins
What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant...
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) – Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
atorvastatin, Lipitor, simvastatin, Repatha, pravastatin, Crestor, Zetia, ezetimibe, rosuvastatin, Praluent, Leqvio